EGFR and non-small cell lung carcinoma: More recently, the effectiveness in the adjuvant setting of biological therapies already used for years in the treatment of advanced stage NSCLC patients has been proven and epidermal growth factor receptor (EGFR) molecular screening has been introduced in the adjuvant setting [5].